Since December 2015, dengue is a vaccine-preventable disease. What are the key factors to consider for vaccine introduction.

The CYD-TDV vaccine (commercial name Dengvaxia®) is a dengue tetravalent vaccine (live attenuated), that has been licensed for the prevention of dengue in more than 20 countries in Latin America and Asia Pacific.

Based on the update label of the manufacturer and the revised WHO position paper on dengue vaccine, a pre-vaccination screening is now the recommended strategy for implementation.

EpiLinks has been involved in:

  • Developing a new Toolkit to summarize key information to help decision makers and program planners (including Ministry of Health staff and NITAG1 members) make country decisions on dengue vaccine introduction
  • Supporting an endemic Asian country workshop on dengue vaccine implementation strategies and impact
  • Communicating lessons learned from previous introduction in public immunization programs (symposium and reports)

National Immunization Advisory Groups

Client/Funder: Fondation Mérieux 

Project duration: 6 months (2018)

Contact: Isabelle Delrieu